OpenResearchAlpha

Clinical Infectious Diseases · 20 Nov 2026

High-Dose vs Standard-Dose Influenza Vaccine and Patient-Reported Symptom Burden in Older Adults – A Substudy of the DANFLU-2 Randomized Clinical Trial

Filip Soeskov Davidovskih-index 12, Kristoffer Grundtvig Skaarup, Christian Sümeghy Søndergaard, Nabila Shaikh, Peter Suldrup Wolff, Jose Bartelt-Hofer, Rebecca C Harris, Matthew M Loiacono, Daniel Modin, Randi Jessen, John M J Lapage, Daniel S Shaw, Nina Steenhard, Cyril Jean-Marie Martel, Carsten Schade Larsen, Lykke Larsen, Lothar Wiese, Michael Dalager-Pedersen, Brian L Claggett, Scott D Solomon, Pradeesh Sivapalan, Jens Ulrik Stæhr Jensen, Niklas Dyrby Johansen, Tor Biering-Sørensenh-index 55

0
Citations
no database records one yet
0
Citations in 2026
so far
55
Leading author's h-index
Tor Biering-Sørensen, in QAI's scholar index
0
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Abstract Background High-dose inactivated influenza vaccine (HD-IIV) reduces laboratory-confirmed influenza (LCI) and severe outcomes compared with standard-dose inactivated influenza vaccine (SD-IIV), but effects on patient-reported symptom burden are uncertain. Objective To compare symptom burden after HD-IIV versus SD-IIV among older adults with symptomatic LCI and assess feasibility of home-based self-swabbing with digital patient-reported outcomes. Design Prespecified exploratory substudy of the randomized, open-label DANFLU-2 trial. Setting Nationwide in Denmark within the DANFLU-2 randomized trial during the 2024 to 2025 influenza season. Participants Community-dwelling adults aged 65 years or older enrolled in DANFLU-2 who consented to participate in the Homeswab substudy. Intervention Participants were assigned 1:1 to HD-IIV or SD-IIV and received self-swab kits with digital symptom questionnaires for influenza-like illness episodes. Measurements Symptom burden among participants with LCI, assessed with the validated Respiratory Infection Intensity and Impact Questionnaire (RiiQ). Feasibility was assessed by swab return, RT-qPCR analyzability, RNase P positivity, and questionnaire completion. Results Among 10,140 randomized participants (HD-IIV, 5040; SD-IIV, 5100; mean age, 73.2 years; 50.3% female), 1280 swabs were received and 1273 were analyzable. 121 swabs (9.5%) tested positive for influenza (HD-IIV, 44; SD-IIV, 77), and RNase P positivity was 97.8% (1245 of 1273). Among participants with LCI, 97 (80.2%) completed at least 1 symptom questionnaire. Respiratory and systemic symptom severity did not differ between groups. Post hoc relative vaccine effectiveness of HD-IIV versus SD-IIV against LCI was 42.2% (95% CI, 16.4% to 60.0%). Limitations The symptom-burden analysis was limited by few breakthrough infections and incomplete questionnaire completion. Conclusion Home-based self-swabbing with digital patient-reported outcome collection was feasible at scale among older adults in a vaccine effectiveness trial, but symptom burden after LCI did not differ between HD-IIV and SD-IIV.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Tor Biering-Sørensen has the highest h-index among the authors (55).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (24)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (0)

What it cites, from open citation data, with Crossref's record of each.

No references in the open citation data yet.